A recent study by Baycrest reveals that an area of the brain distinct from the stroke lesion may play a significant role in causing the life-altering symptoms survivors are often left with, which can ...
The End-of-Phase 2 meeting resulted in alignment with the FDA on the proposed Phase 3 study design, including the inclusion/exclusion criteria, primary and secondary efficacy objectives, definition of ...